Cargando…
B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages
B cell maturation antigen (BCMA), a transmembrane glycoprotein member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17), highly expressed on the plasma cells of Multiple myeloma (MM) patients, as well as the normal population. BCMA is used as a biomarker for MM. Two members of the TNF...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832753/ https://www.ncbi.nlm.nih.gov/pubmed/35144648 http://dx.doi.org/10.1186/s12967-022-03285-y |
_version_ | 1784648784726196224 |
---|---|
author | Nobari, Shirin Teymouri Nojadeh, Jafar Nouri Talebi, Mehdi |
author_facet | Nobari, Shirin Teymouri Nojadeh, Jafar Nouri Talebi, Mehdi |
author_sort | Nobari, Shirin Teymouri |
collection | PubMed |
description | B cell maturation antigen (BCMA), a transmembrane glycoprotein member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17), highly expressed on the plasma cells of Multiple myeloma (MM) patients, as well as the normal population. BCMA is used as a biomarker for MM. Two members of the TNF superfamily proteins, including B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), are closely related to BCMA and play an important role in plasma cell survival and progression of MM. Despite the maximum specificity of the monoclonal antibody technologies, introducing the tumor-specific antigen(s) is not applicable for all malignancies, such as MM that there plenty of relatively specific antigens such as GPCR5D, MUC1, SLAMF7 and etc., but higher expression of BCMA on these cells in comparison with normal ones can be regarded as a relatively exclusive marker. Currently, different monoclonal antibody (mAb) technologies applied in anti-MM therapies such as daratuzumab, SAR650984, GSK2857916, and CAR-T cell therapies are some of these tools that are reviewed in the present manuscript. By the way, the structure, function, and signaling of the BCMA and related molecule(s) role in normal plasma cells and MM development, evaluated as well as the potential side effects of its targeting by different CAR-T cells generations. In conclusion, BCMA can be regarded as an ideal molecule to be targeted in immunotherapeutic methods, regarding lower potential systemic and local side effects. |
format | Online Article Text |
id | pubmed-8832753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88327532022-02-11 B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages Nobari, Shirin Teymouri Nojadeh, Jafar Nouri Talebi, Mehdi J Transl Med Review B cell maturation antigen (BCMA), a transmembrane glycoprotein member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17), highly expressed on the plasma cells of Multiple myeloma (MM) patients, as well as the normal population. BCMA is used as a biomarker for MM. Two members of the TNF superfamily proteins, including B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), are closely related to BCMA and play an important role in plasma cell survival and progression of MM. Despite the maximum specificity of the monoclonal antibody technologies, introducing the tumor-specific antigen(s) is not applicable for all malignancies, such as MM that there plenty of relatively specific antigens such as GPCR5D, MUC1, SLAMF7 and etc., but higher expression of BCMA on these cells in comparison with normal ones can be regarded as a relatively exclusive marker. Currently, different monoclonal antibody (mAb) technologies applied in anti-MM therapies such as daratuzumab, SAR650984, GSK2857916, and CAR-T cell therapies are some of these tools that are reviewed in the present manuscript. By the way, the structure, function, and signaling of the BCMA and related molecule(s) role in normal plasma cells and MM development, evaluated as well as the potential side effects of its targeting by different CAR-T cells generations. In conclusion, BCMA can be regarded as an ideal molecule to be targeted in immunotherapeutic methods, regarding lower potential systemic and local side effects. BioMed Central 2022-02-10 /pmc/articles/PMC8832753/ /pubmed/35144648 http://dx.doi.org/10.1186/s12967-022-03285-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Nobari, Shirin Teymouri Nojadeh, Jafar Nouri Talebi, Mehdi B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages |
title | B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages |
title_full | B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages |
title_fullStr | B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages |
title_full_unstemmed | B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages |
title_short | B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages |
title_sort | b-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832753/ https://www.ncbi.nlm.nih.gov/pubmed/35144648 http://dx.doi.org/10.1186/s12967-022-03285-y |
work_keys_str_mv | AT nobarishirinteymouri bcellmaturationantigentargetingstrategiesinmultiplemyelomatreatmentadvantagesanddisadvantages AT nojadehjafarnouri bcellmaturationantigentargetingstrategiesinmultiplemyelomatreatmentadvantagesanddisadvantages AT talebimehdi bcellmaturationantigentargetingstrategiesinmultiplemyelomatreatmentadvantagesanddisadvantages |